Latest Coagulation Stories
BEDFORD, Mass., Feb. 5, 2013 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of their new HemosIL AcuStar von Willebrand Factor (VWF) assay panel as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. The CE IVD Mark allows IL to commence distribution of the product in the European Union and other international territories. The fully automated HemosIL AcuStar VWF assay panel, designed exclusively for use on...
An international study led by King's College London has identified a new genetic variant associated with stroke An international study led by King's College London has identified a new genetic variant associated with stroke. By exploring the genetic variants linked with blood clotting – a process that can lead to a stroke – scientists have discovered a gene which is associated with large vessel and cardioembolic stroke but has no connection to small vessel stroke. Published in the...
KING OF PRUSSIA, Pa., Jan. 30, 2013 /PRNewswire/ -- CSL Behring announced today that it has awarded $78,750 in Local Empowerment for Advocacy Development (LEAD) grants to patient advocacy organizations in New York and Ohio, and to the American Plasma Users Coalition (APLUS). LEAD grants are intended to help local patient organizations achieve their advocacy objectives by further developing an existing initiative or creating a new one. (Logo:...
KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). The study site for this first enrollment is the Czech Republic. "CSL continues to advance at a very encouraging rate with...
MARBURG, Germany, Dec. 19, 2012 /PRNewswire/ -- Clinical study results published today in the journal Anesthesiology showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery. The Phase II prospective study, performed by CSL Behring and collaborators at the Hannover Medical School, Germany, enrolled 61...
WAYNE, N.J., Nov. 28, 2012 /PRNewswire/ -- Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete. Recruitment is ongoing at sites located around the world, including in the U.S., where sites are ready to enroll eligible patients. The TRUST trial is designed to evaluate the safety and efficacy of the investigational compound BAY 86-6150, a...
New insights into what causes uncontrollable bleeding in hemophilia patients are provided in a study published by Cell Press on November 20th in the Biophysical Journal. By revealing that blood clots spread in traveling waves through vessels, the study offers new strategies that could lead to the development of more effective treatments for hemophilia as well as common cardiovascular disorders. "Disorders of blood coagulation are a leading and immediate cause of mortality and morbidity in...
ORLANDO, Fla., Nov. 8, 2012 /PRNewswire/ -- A coalition of leaders in hemophilia advocacy and treatment today announced a nationwide program that will offer free genetic testing to people with hemophilia and their families. The partnership will be officially unveiled this evening at the 64(th) National Hemophilia Foundation (NHF) Annual Meeting in Orlando, Florida. To view the multimedia assets associated with this release, please click:...
CARLSBAD, Calif., Oct. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXI(Rx) in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA). ISIS-FXI(Rx) inhibits the production of Factor XI, a coagulation factor produced in the liver that is involved in the formation of clots. In this study, Isis will evaluate the effectiveness of ISIS-FXI(Rx)...
BEIJING, Oct. 24, 2012 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang") has received good manufacturing practice ("GMP") certification from the China State Food and Drug Administration ("SFDA") for Human Coagulation Factor VIII ("FVIII")....
